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A B S T R A C T
Background: Dengue and chikungunya co-infections are an emerging threat to public health in tropical and sub-
tropical areas. This study investigates acute and long-term clinical presentation patterns of chikungunya against
a backdrop of preceding dengue infection and determines predicting factors for long-term chikungunya sequelae.
Methods: A retrospective cohort study was performed in 2015, including 299 previously conﬁrmed chikungunya
cases, of which 162 subjects were assessed for dengue serology at disease onset.
Results: Those with previous dengue infection (35.2% of the examined population) had a similar acute disease
presentation, and suﬀered (not statistically signiﬁcantly) more frequently from long-term musculoskeletal and
neuropsychological symptoms compared to chikungunya-only patients. Patients with a preceding dengue in-
fection (vs. those without) (OR=4.17; p=0.004), female sex (OR=3.17; p= 0.034) and pre-existing joint
disease (OR=2.95; p=0.031) had a higher risk of developing aggravated long-term chikungunya. Chronic
disease (sequelae lasting> 90 days) was predicted by an age between 41 and 60 (OR=3.07; p=0.009) and
concomitant cardiovascular disease (OR=4.08; p=0.010), but not by a preceding dengue infection.
Conclusions: This study suggests several predicting factors of, and a possible link between preceding dengue and
chikungunya infection and aggravated long-term sequelae, which should be interpreted in the light of the
limitations of this study.
1. Introduction
Dengue and chikungunya are arboviruses transmitted by the day-
biting mosquitoes Aedes aegypti and Aedes albopictus [1,2]. The vectors
of these viruses currently circulate in large parts of the world, rendering
40% of the world population susceptible to these diseases [3]. Chi-
kungunya led to devastating epidemics when introduced in the Amer-
icas at the end of 2013 [4,5]. In the same regions, dengue is endemic
with an increasing spread to previously unaﬀected areas [6]. Con-
comitant dengue and chikungunya infection have been reported in
several regions worldwide, in particular in Africa and Asia [7]. How-
ever, considering the high transmission rates of both diseases, co-
infections of dengue and chikungunya are surprisingly little reported
[8,9]. Saint Martin, a Caribbean island where the ﬁrst locally trans-
mitted chikungunya cases were reported in the Caribbean and America,
also described the ﬁrst co-infections of dengue and chikungunya in
these regions [10].
Curaçao became aﬀected by the epidemic of chikungunya up from
mid-2014. The outbreak rapidly spread and at the end of the epidemic
in January 2015, an estimated 50,000 to 75,000 inhabitants were in-
fected [IG, unpublished]. This epidemic took place in a naïve popula-
tion for chikungunya against the backdrop of well-established dengue
transmission, with outbreaks during the rainy season [11]. All four
dengue virus serotypes co-circulate in Curaçao [11].
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Dengue and chikungunya lead to similar acute clinical presenta-
tions, typically starting with an abrupt onset of fever, which may be
accompanied by a range of symptoms such as rash, headache, myalgia
and arthralgia [1,2]. Disease may evolve into severe conditions and
cause death in the case of dengue [2], while chikungunya is recognized
for its debilitating long-lasting musculoskeletal symptoms, which may
persist for years [12–14]. The clinical spectrum of dengue and chi-
kungunya co-infections is not well described, and focuses on acute
disease manifestations or complications. These studies do not show
substantial diﬀerences in disease presentation [15–17]; however,
complicated disease was described in co-infected patients [17].
To assess the knowledge gap concerning infections of chikungunya
and dengue, this study investigated the impact of a preceding dengue
infection on acute and chronic chikungunya disease presentation and
analysed predicting factors for chronic sequelae.
2. Study methods
During June and July 2015, a retrospective cohort study was set up
including laboratory conﬁrmed (by serology (ELISA), reverse tran-
scription polymerase chain reaction (RT-PCR) or indirect ﬂuorescent
antibody (IFA)) chikungunya cases infected during the 2014 epidemic
in Curaçao. Participant recruitment procedures and study site were
described elsewhere [18]. Brieﬂy, adult participants' data was provided
by general practitioners, working in 14 practices across Curaçao. As-
sessment of long-term chikungunya sequelae was performed in the
homes of participants as part of a cross-sectional survey study.
2.1. Study objectives
This study has diﬀerent objectives. These objectives have distinct
inclusion criteria (see Fig. 1), and therefore the sample size diﬀers per
objective. The objectives with their inclusion criteria are presented in
Fig. 1 and are as follows:
- Objective 1: To analyse acute clinical presentation of preceding
dengue infection and chikungunya-only disease. Inclusion criteria:
subjects with clinical data of acute disease presentation and avail-
able dengue serology (n=94);
- Objective 2: To analyse predicting factors of chronic disease out-
comes: (a)severe disease development and (b) disease persis-
tence>90 days. Inclusion criteria: subjects with clinical data of
acute disease presentation (n=159);
- Objective 3: To analyse chronic clinical presentation of preceding
dengue infection and chikungunya-only disease. Inclusion criteria:
subjects with available dengue serology (n= 162).
2.2. Data collection
Individuals were surveyed using a structured questionnaire asses-
sing socioeconomic variables, co-morbidities, chronic chikungunya se-
quelae and chikungunya disease status; the latter being assessed using
the formerly described Curaçao Long-Term Chikungunya Sequelae
(CLTCS) score, where individuals with chronic chikungunya sequelae
were classiﬁed as ‘recovered’, ‘mildly aﬀected’ or ‘highly aﬀected’ [18].
Trained, experienced local interviewers applied the questionnaire,
which was piloted and adapted in Dutch, and translated to Papiamentu,
Spanish and English [18].
The Ministry of Health of Curaçao is responsible for disease sur-
veillance. During outbreaks, physicians are requested to report any
suspected case to the Ministry of Health. Data from acute disease pre-
sentation was acquired via general practitioners, who assessed sus-
pected chikungunya cases using a standardized form for chikungunya
surveillance (Table 1) and referred them for dengue serology. Enzyme-
linked immunosorbent assay (ELISA; DxSelect™, Focus Diagnostics) of
acute samples and, if available, convalescent samples was performed by
the Analytical Diagnostic Centre (ADC N·V.) in Curaçao according to the
manufacturer's protocol, to detect dengue-speciﬁc IgM and IgG.
2.3. Classiﬁcation of dengue serology
Classiﬁcation of serologic outcomes was determined as presented in
Table 2.
We expected that a positive IgM for dengue and laboratory con-
ﬁrmed dengue could inﬂuence clinical manifestations. Therefore, pa-
tients diagnosed with an acute or presumptive/recent dengue infection
were merged into one group, to which we hereinafter refer as ‘pre-
ceding dengue’. On the other hand, the ‘past dengue’ and the ‘negative
cases’ were merged and are hereinafter referred to as chikungunya-only
(i.e. no preceding dengue infection).
2.4. Data analysis
Data analysis procedures were described elsewhere [18]. Brieﬂy,
odds ratios of acute and chronic symptoms were calculated and ad-
justed for confounding factors using a binary logistic regression. Pos-
sible confounding of acute or chronic clinical presentation between
individuals with chikungunya-only and a preceding dengue disease
Fig. 1. Flowchart inclusion proce-
dure of the study population.
Objective 1: To analyse acute clinical
presentation of preceding dengue in-
fection and chikungunya-only disease.
Objective 2: To analyse predicting fac-
tors of chronic disease outcomes: (a)
severe disease development and (b)
disease persistence> 90 days.
Objective 3: To analyse chronic clinical
presentation of preceding dengue in-
fection and chikungunya-only disease.
Additional analyses: these analyses are
presented in Appendix A, and were
additionally performed since the
sample size in the main manuscript was
limited. The additional analyses also
include the sample which was not
tested for dengue. Therefore, these re-
sults should be interpret with caution.
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episode due to age, sex and co-morbidity was explored (Table 3).
Variables associated with a preceding dengue infection at a p≤ 0.200
level were considered as confounding variables, namely concomitant
diabetes mellitus and cardiovascular disease (for acute and chronic
clinical presentation) and age (for chronic clinical presentation)
(Table 3). The same procedures were performed in the additional
analyses presented in Appendix A.
A multivariate binary logistic regression was performed to in-
vestigate predicting factors of chronic chikungunya (sequelae lasting
longer than 90 days), and ‘highly severe’ chronic chikungunya disease
outcomes, based on the CLTCS-score. The ‘highly severe’ disease status
was chosen, because it reﬂects a chronic chikungunya disease status
associated with severely reduced quality of life [18]. The multivariate
analyses included all clinical and general characteristic variables which
were associated with the dependent variables at a signiﬁcance level of
p < 0.20. To obtain more insights and power, additional analyses of
acute and chronic disease presentation were performed in Appendix A.
These analyses followed the same procedures as the main manuscript,
but included the participants without available dengue serology and
should therefore be interpreted with caution.
2.5. Ethics statement
The study was approved by the Medical Ethical Board of the Sint
Elisabeth Hospital (METC SEHOS) Curaçao (Reference number:
2015–002). All participants enrolled consented in writing.
3. Results
In June and July 2015, 304 laboratory-conﬁrmed chikungunya
cases were included in a cohort study (Fig. 1). The socio-economic
characteristics of the individuals were described previously [18]. Of the
304 individuals, 299 consented to participate in the present study of
which 162 were tested for dengue exposure. Fifty-seven participants
were deﬁned as having had a preceding dengue infection. Of those, 11
had a laboratory conﬁrmed dengue and 46 a ‘presumptive/recent
Table 1
Univariate analysis of acute clinical presentation of chikungunya, comparing individuals with vs. without preceding dengue infection.
Chikungunya-only infection (n= 58) Preceding dengue infection (n = 36)* Adjusted ORa (95% CI) Adjusted p-valuea
n (%) n (%)
Acute symptoms (n)b
Fever (n= 56; n= 36) 54 (96.4) 32 (88.9) 0.35 (0.06–2.13) 0.253
Headache (n= 57; n=36) 50 (87.7) 30 (83.3) 1.10 (0.64–5.60) 0.890
Orbital pain (n=53; n= 35) 38 (71.7) 21 (60.0) 0.72 (0.90–12.26) 0.512
Myalgia (n=56; n= 35) 53 (94.6) 34 (97.1) 2.96 (0.27–32.31) 0.373
Arthralgia (n= 56; n= 36) 53 (94.6) 34 (94.4) 1.65 (0.22–12.52) 0.628
Arthritis (n= 55; n=35) 35 (63.6) 26 (74.3) 1.62 (0.61–4.32) 0.335
Rash (n= 57; n= 35) 27 (47.4) 15 (42.9) 1.04 (0.43–2.55) 0.637
Nausea/vomiting (n=57; n= 36) 19 (33.3) 12 (33.3) 0.98 (0.39–2.44) 0.962
Diarrhoea (n= 56; n=36) 14 (25.0) 7 (19.4) 0.75 (0.26–2.18) 0.603
Cold shivers (n= 55; n=36) 29 (52.7) 17 (47.2) 0.89 (0.37–2.17) 0.801
Cough (n= 57; n= 35) 16 (28.1) 2 (5.7) 0.14 (0.03–0.71) 0.017
Haemorrhagic tendencies (n= 57; n= 35) 3 (5.3) 0 (0.0) – 0.168*
Icterus (n= 56; n= 35) 1 (1.8) 1 (2.9) 0.51 (0.02–11.39) 0.669
p-values in bold are statistically signiﬁcant.
*Fisher's exact test.
a p-value and OR corresponds to the comparison of ‘preceding dengue infection’ vs. ‘chikungunya-only infection’, adjusted for concomitant diabetes mellitus and
cardiovascular disease.
b number of subjects in the ‘chikungunya-only infection’ group and the ‘preceding dengue infection’ group, respectively.
Table 2
Categorisation of ELISA assessments.
Acute sample Convalescent sample Classiﬁcation Binary categorisation for analyses
IgM IgG IgM IgG n (%)a
P N P P 1 (0.6) Acute dengue Preceding dengue infection and chikungunya
N P P P 6 (3.7) Acute dengue Preceding dengue infection and chikungunya
N N N P 2 (1.2) Acute dengue Preceding dengue infection and chikungunya
P N – – 1 (0.6) Acute dengue Preceding dengue infection and chikungunya
N P N P 1 (0.6) Acute dengueb Preceding dengue infection and chikungunya
P P – – 38 (23.5) Presumptive/recent dengue Preceding dengue infection and chikungunya
P P N P 2 (1.2) Presumptive/recent dengue Preceding dengue infection and chikungunya
P P P P 4 (2.5) Presumptive/recent dengue Preceding dengue infection and chikungunya
– – P P 2 (1.2) Presumptive/recent dengue Preceding dengue infection and chikungunya
N P N P 26 (16.0) Past dengue Chikungunya-only
N P – – 70 (43.2) Past dengue Chikungunya-only
– – N P 6 (3.7) Past dengue Chikungunya-only
N N N N 1 (0.6) Conﬁrmed dengue negative Chikungunya-only
N N – – 2 (1.2) Presumptive dengue negative Chikungunya-only
P=positive test outcome; N=negative test outcome; aTotal subjects with dengue serology: n=162; bThis concerned one case. Because values of the convalescent
sample rose by more than 5 times, this sample was considered as IgG seroconversion.Classiﬁcation: Patients were deﬁned as having an ‘acute dengue infection’,
‘presumptive/recent dengue’ or ‘past dengue’. A dengue infection was assumed as a ‘laboratory conﬁrmed dengue’ based on a conversion of IgM or IgG in paired
samples, or on a positive IgM in a previously naïve individual (i.e. negative IgG) in the acute sample. Participants were deﬁned as having had a ‘preceding dengue’
infection when IgM was positive in one of the samples (i.e. in the acute or convalescent sample). Cases were deﬁned as ‘past dengue’ when IgM was negative and IgG
positive. When IgG and IgM tests were negative in acute (and convalescent) sample(s), cases were deﬁned as (laboratory conﬁrmed) ‘dengue negative’.
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dengue infection’ (Fig. 1). Prevalence of chikungunya with a preceding
dengue infection (which included the 46 ‘presumptive/recent’, and the
11 laboratory conﬁrmed participants) was thereby 35.2% (57/162).
3.1. Acute clinical presentation
To understand if the acute disease presentation of chikungunya was
inﬂuenced by a preceding dengue infection, symptoms assessed by
general practitioners were compared and adjusted for concomitant
diabetes mellitus and concomitant cardiovascular disease (Table 1).
Cough was more frequently reported in individuals with only chi-
kungunya (chikungunya: 18.1% [n=16] vs. preceding dengue infec-
tion: 5.7% [n=2]; adjusted p-value= 0.017). No other symptoms of
acute presentation were associated with having a chikungunya-only or
preceding dengue, neither in the additional analyses in Tables A1, A2.
3.2. Predicting factors of disease outcomes
Clinical characteristics of long-term chikungunya sequelae were
assessed between 92 and 419 days after onset of acute disease. Uni- and
multivariate analyses were performed to identify predicting factors of
two disease outcomes: 1) chikungunya disease persistence> 90 days,
and 2) development of a ‘highly aﬀected’ CLTCS-disease status. In
66.5% (n=105) of the cases, chikungunya disease persisted> 90 days
and 25.8% (n=41) were ‘highly aﬀected’ at time of interview. Time-
between-interview and disease onset was assessed as potential con-
founder, but showed a similar distribution for the ‘recovered and mildly
aﬀected’ and ‘highly aﬀected’ individuals (Mean=267 days, SD=75
days vs. Mean= 258 days, SD=57 days; T-test: p= 0.431). In the
univariate analysis, disease outcomes were compared with socio-eco-
nomic characteristics, co-morbidity and clinical presentation at acute
disease presentation (Table 4). Variables associated at a level of
p≤ 0.20 were included in the multivariate analysis. The ﬁnal models of
the multivariate analysis are presented in Table 5. An age between 41
and 60 (OR=3.07; p= 0.009) (baseline category: age of 18–40) and
concomitant cardiovascular disease (OR=4.08; p= 0.010) were in-
dependent predictors of chikungunya disease longer than 90 days.
‘Highly aﬀected’ disease status was predicted by female sex (OR=3.17;
p=0.034), concomitant joint disease (OR=2.91; p=0.031) and
preceding dengue (OR=4.17; p=0.004) (although the baseline
category ‘no dengue serology’ was used).
3.3. Long-term sequelae
Clinical chronic chikungunya presentation of the 162 individuals
was compared between those with and without a preceding dengue
infection, adjusted for age, concomitant diabetes mellitus and con-
comitant cardiovascular disease. Participants with a preceding dengue
infection at disease onset reported higher proportions of most chronic
symptoms (Table 6, Fig. 2, Table A3), but no signiﬁcant associations
were found. Chronic joint pain in lower extremities was associated with
a preceding dengue infection (OR=1.86; p=0.044) in the additional
analyses in Table A3.
4. Discussion
In June and July 2015, a retrospective cohort study was performed
to investigate the inﬂuence of a preceding dengue infection on chi-
kungunya disease development. Chikungunya and a preceding dengue
infection covered 35.2% of the subjects serologically tested for both
diseases, which is amongst the highest incidences reported to date. As
reviewed by Furuya-Kanamori and colleagues, the vast majority of
studies report incidences of ‘co-infections’ up to 10% of the study po-
pulation [19]. Most of these studies assessing ‘co-infection’ relied, like
the present study, (partly) on ELISA-IgM assessment when estimating
concomitant prevalence of chikungunya and dengue. It is important to
note here that ELISA-IgM assessment alone is not speciﬁc enough to
deﬁne co-infection.
Very few studies describe acute clinical disease presentation of
chikungunya and a preceding dengue infection [8,20]. Even fewer of
these included chikungunya-only infections and show, like the present
study, no major diﬀerences with preceding or co-infected subjects in
acute disease presentation [15–17] but reported complicated disease
manifestations [17]. It is notable that patients with chikungunya and a
preceding dengue infection were assessed as having more myalgia
(OR=3.0) and arthritis (OR=1.6). This contradicts the ﬁndings of the
study by Taraphdar et al. where patients with a preceding dengue in-
fection and chikungunya presented with milder musculoskeletal man-
ifestation than the chikungunya-only infected population [15]. Acute
chikungunya (without preceding dengue) presented more often with
Table 3
Analysis of possible confounders on acute and chronic disease presentation.
Sample with dengue serology and clinical data on acute disease presentation
(n= 94)










n (%) n (%) n (%) n (%)
Age
18–40 16 (27.6) 6 (16.7) 30 (28.6) 9 (15.8)
41–60 35 (60.3) 24 (66.7) 55 (52.4) 37 (64.9)
> 61 7 (12.1) 6 (16.7) 0.484* 20 (19.0) 11 (19.3) 0.171
Sex
Male 14 (24.1) 9 (25.0) 27 (25.7) 12 (21.1)
Female 44 (75.9) 27 (75.0) 0.925 78 (74.3) 45 (78.9) 0.507
Co-morbidity
Joint disease 8 (13.8) 6 (16.7) 0.704 15 (14.3) 10 (17.5) 0.584
Cardiovascular diseasec 9 (15.5) 10 (27.8) 0.150 15 (14.3) 13 (22.8) 0.171
Neurologic disease 1 (1.7) 1 (2.8) 1.000* 2 (1.9) 3 (5.3) 0.346*
Diabetes mellitus 4 (6.9) 8 (22.2) 0.053* 9 (8.6) 11 (19.3) 0.047
p-values in bold are statistically signiﬁcant.
*Fisher's exact test.
a p-value corresponds to the comparison between the groups ‘chikungunya-only infection’ and ‘preceding dengue infection’.
b Cardiovascular disease group includes hypercholesterolemia and hypertension.
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cough when compared to chikungunya with recent dengue (OR=7.1;
p=0.017). Cough is a relatively infrequent symptom at acute disease
and might diﬀerentiate between a chikungunya-only infection and a
chikungunya with recent dengue, although we could not ﬁnd a patho-
physiological explanation for this ﬁnding. Compared to other studies on
acute chikungunya disease presentation, this study reported similar
proportions of fever [21–25], arthralgia [21–24,26] and rash [22–25]
while myalgia [21,23,24,26] and headache [21,23–25] were reported
in higher proportions. These results indicate that diﬀerentiating be-
tween chikungunya-only infections and infections of chikungunya with
recent dengue at acute presentation remains diﬃcult and depends on
laboratory assessment.
This is the ﬁrst study describing that chikungunya with preceding
dengue at acute disease presentation is a predicting factor (OR=4.1)
for severe chronic disease development. This independent association
was most prominent when compared to the subjects without available
dengue serology, but not signiﬁcant (OR=1.9; p= 0.159) when
compared to the chikungunya-only subjects. It is likely that the group
without available dengue serology consisted mainly of ‘past dengue’ or
‘dengue negative’ subjects, whilst a lower proportion would have had
dengue before. Therefore, we conclude that the latter bias may only
have led to an underestimation of diﬀerences between the two groups.
The independent association of dengue infection preceding chi-
kungunya and developing a ‘highly aﬀected’ chronic disease status was
reﬂected in the chronic clinical presentation, where the vast majority of
chronic symptoms was reported in higher proportions in this group (i.e.
Table 4
Univariate analysis of chikungunya disease outcome parameters: disease persistence longer than 90 days and highly aﬀected CLTCS-disease status.





n (%) n (%) n (%) n (%)
Age
18–40 18 (34.0) 15 (14.3) 28 (23.7) 6 (14.6)
41–60 24 (45.3) 71 (67.6) 65 (55.1) 30 (73.2)
> 61 11 (20.8) 19 (18.1) 0.008 25 (21.2) 5 (12.2) 0.126
Sex
Male 15 (28.3) 23 (21.9) 33 (28.0) 5 (12.2)
Female 38 (71.7) 82 (78.1) 0.374 85 (72.0) 36 (87.8) 0.041
Education
Illiterate/primary school 11 (20.8) 23 (21.9) 24 (20.3) 10 (24.4)
Secondary school 16 (30.2) 37 (35.2) 39 (33.1) 14 (34.1)
Intermediate vocational education 16 (30.2) 27 (25.7) 37 (31.4) 7 (17.1)
University (of applied sciences) 10 (18.9) 18 (17.1) 0.895 18 (15.3) 10 (24.4) 0.269
Occupation
Unemployed/student/housewife/voluntary 9 (17.0) 12 (11.4) 16 (13.6) 5 (12.2)
Paid job (domestic or manual) 22 (41.5) 53 (50.5) 54 (45.8) 22 (53.7)
Paid job (not domestic or manual) 16 (30.2) 23 (21.9) 30 (25.4) 9 (22.0)
Retired 6 (11.3) 17 (16.2) 0.708* 18 (15.3) 5 (12.2) 0.853
Income (n1= 156; n2= 157)
0-999 ANG 4 (7.7) 9 (8.7) 10 (8.5) 3 (7.5)
1000-2499 ANG 19 (36.5) 39 (37.5) 39 (33.3) 19 (47.5)
2500-4999 ANG 20 (38.5) 45 (43.3) 52 (44.4) 14 (35.0)
> 5000 ANG 9 (17.3) 11 (10.6) 0.691 16 (13.7) 4 (10.0) 0.314*
Co-morbidity
Joint disease 3 (5.7) 19 (18.1) 0.033 12 (10.2) 10 (24.4) 0.023
Cardiovascular diseasec 5 (9.4) 31 (29.5) 0.004 25 (21.2) 11 (26.8) 0.457
Neurologic disease 0 (0.0) 2 (1.9) 0.551* 2 (1.7) 0 (0.0) 1.000*
Diabetes mellitus 5 (9.4) 12 (11.4) 0.702 11 (9.3) 6 (14.6) 0.382*
Dengue assessment
Preceding dengue infection 22 (41.5) 43 (41.0) 21 (17.8) 10 (24.4)
Past dengue/dengue negative 21 (39.6) 36 (34.3) 42 (35.6) 16 (39.0)
No dengue serology 22 (41.5) 43 (41.0) 0.664 55 (46.6) 15 (36.6) 0.014
Acute symptoms
Fever (n1=&#x202f;51&101; n2= 112&41) 45 (88.2) 95 (94.1) 0.219* 102 (91.1) 39 (95.1) 0.516*
Headache (n1=52&105; n2= 41&117) 41 (78.8) 85 (81.0) 0.755 92 (78.6) 35 (85.4) 0.350
Orbital pain (n1= 51&99; n2= 113&38) 28 (54.9) 64 (64.6) 0.246 66 (58.4) 26 (68.4) 0.274
Myalgia (n1= 52&103; n2= 116&40) 48 (92.3) 97 (94.2) 0.733* 107 (92.2) 39 (97.5) 0.454*
Arthralgia (n1= 52&104; n2=116&41) 51 (98.1) 97 (93.3) 0.270* 109 (94.0) 40 (97.6) 0.681*
Arthritis (n1=51&97; n2=108&41) 30 (58.8) 61 (62.9) 0.629 63 (58.3) 29 (70.7) 0.164
Rash (n1= 53&102; n2=115&41) 21 (39.6) 46 (45.1) 0.514 48 (41.7) 20 (48.8) 0.435
Nausea/vomiting (n1= 52&104; n2= 116&
41)
12 (23.1) 41 (39.4) 0.042 35 (30.2) 18 (43.9) 0.110
Diarrhoea (n1=51&104; n2= 115&41) 11 (21.6) 22 (21.2) 0.953 24 (20.9) 9 (22.0) 0.884
Cold shivers (n1=51&103; n2= 114&41) 22 (43.1) 50 (48.5) 0.527 51 (44.7) 21 (51.2) 0.475
Cough (n1= 53&102; n2= 115&41) 8 (15.1) 16 (15.7) 0.923 16 (13.9) 8 (19.5) 0.394
Haemorrhagic tendencies (n1= 53&102;
n2=115&41)
2 (3.8) 2 (2.0) 0.607* 4 (3.5) 0 (0.0) 0.574*
Icterus (n1= 53&101; n2=115&40) 2 (3.8) 0 (0.0) 0.117* 2 (1.7) 0 (0.0) 1.000*
p-values in bold are statistically signiﬁcant.
*Fisher's exact test.
a p-value corresponds to the comparison between the groups ‘0–90 days’ and ‘>90 days’.
b p-value corresponds to the comparison between the groups ‘recovered and mildly aﬀected’ and ‘highly aﬀected’.
c Cardiac disease group includes hypercholesterolemia and hypertension; n1 refers to the number of subjects of the ‘0–90 days’ and ‘>90 days’ group respectively;
n2 refers to the number of subjects of the ‘Recovered & mildly aﬀected’ and ‘Highly aﬀected’ group respectively.
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arthralgia, myalgia, fatigue, insomnia and neuropsychological symp-
toms). In particular the higher proportions of chronic joint pain in the
lower extremities, which have previously been associated with the
‘highly aﬀected’ disease status [18], may be responsible for this asso-
ciation. The outcomes of the analyses on predicting factors and chronic
disease manifestations might suggest that a preceding dengue infection
aggravates chronic (chikungunya) sequelae. However, the results of this
study alone are not suﬃcient enough to draw a strong conclusion about
this.
Several studies that focused on predicting chikungunya disease
persistence have identiﬁed age [27–29], sex [29], co-morbidity
[27,30], or acute disease presentation [27–30] as determinants, but did
not assess preceding/co-infection of dengue. This study also identiﬁed
age, co-morbidity (joint disease and cardiovascular disease) and female
sex as predicting factors for longer or worse disease outcome. These
predicting factors may aid in assessing the need to follow up chi-
kungunya patients. Furthermore, they may guide further fundamental
research on the poorly understood pathophysiology of chikungunya and
dengue co-infections.
In this manuscript, we assessed the inﬂuence of (preceding) dengue
on chikungunya sequelae. It is important to note that diagnosis of
chikungunya was based on laboratory testing and clinical evaluation by
a physician. When both IgM serology of dengue and chikungunya were
positive following acute disease, it was hard to say which of the two
diseases caused the acute disease manifestations in this case, and in
which order these diseases aﬄicted the patient. However, it is likely
that chikungunya played the most signiﬁcant role in the acute phase,
considering the opinion of the physician and that asymptomatic disease
is less common in chikungunya than in dengue. Therefore, we choose to
refer to these cases as ‘chikungunya with preceding dengue’.
An important limitation of this study was the small sample size of
participants tested for dengue (162/299), with consequent implications
for the power and representativeness of the study. Parallel analyses
were done on acute and long-term clinical presentation to obtain higher
power in the analyses (presented in Appendix A). The results of Table
A1-A3 should be interpreted with caution, because it is likely that some
of the subjects without dengue serology had a preceding dengue in-
fection. Since little is known about clinical presentation of chikungunya
with preceding dengue infection in other contexts than in Curaçao,
generalization of this study should be limited. Due to the recruiting
procedures, a referral bias can be present in this study. Also, in some
cases laboratorial assessment relied on serology of one sample, which
may have lowered the probability to determine a dengue infection.
Further, ELISA-based serological assays of dengue are less reliable than
RT-PCR or viral isolation and might cross-react with (vaccines of)
various ﬂaviviruses (e.g. Japanese encephalitis, yellow fever). How-
ever, based on the epidemiological situation of Curaçao at the time of
the study, we have no reasons to assume that cross-reaction has sig-
niﬁcantly inﬂuenced the results of this study.
Chikungunya sequelae were prominent in the population with a
preceding dengue infection (which included patients with an acute
dengue infection) and chikungunya disease, suggesting survival of
chikungunya virus during concurrent dengue infection. Though severe
Table 5
Final model of variables independently associated with chikungunya disease
outcome parameters: a) duration longer than 90 days vs. 0–90 days; b) highly
aﬀected vs. recovered & mildly aﬀected at time of interview.




41–60 3.07 (1.32–7.11) 0.009
> 61 1.31 (0.44–3.89) 0.625
Co-morbidity: cardiovascular disease
No 1
Yes 4.08 (1.39–11.93) 0.010
Highly aﬀected disease status
Sex
Male 1
Female 3.17 (1.09–9.23) 0.034
Co-morbidity: joint disease
No 1
Yes 2.95 (1.11–7.86) 0.031
Dengue assessment
Preceding (/acute) dengue infection 1 0.016
Past dengue/dengue negative 0.52 (0.21–1.29) 0.159
No dengue serology 0.24 (0.09–0.63) 0.004
Table 6
Chronic chikungunya clinical presentation: preceding dengue infection vs. chikungunya-only infection.
Chikungunya-only infection (n= 105) Preceding dengue infection (n= 57) Adjusted Adjusted
n n n (%) ORa (95% CI) p-valuea
Joint pain in the …
upper extremities 45 (42.9) 24 (42.1) 0.80 (0.40–1.59) 0.525
lower extremities 42 (40.0) 31 (54.4) 1.65 (0.84–3.24) 0.148
Back/neck 31 (29.5) 17 (29.8) 0.92 (0.44–1.91) 0.826
Weakness in the …
upper extremities 39 (37.1) 23 (40.4) 0.98 (0.49–1.95) 0.943
lower extremities 69 (34.3) 25 (43.9) 1.39 (0.70–2.74) 0.351
back/neck 26 (24.8) 15 (26.3) 0.95 (0.44–2.06) 0.902
Myalgiab 31 (29.8) 23 (40.4) 1.36 (0.67–2.74) 0.394
Fatigue 35 (33.3) 21 (36.8) 1.15 (0.58–2.31) 0.686
Insomnia 29 (27.6) 21 (36.8) 1.47 (0.72–3.01) 0.292
Sombreness 16 (15.2) 10 (17.5) 1.02 (0.42–2.51) 0.958
Loss of vitality 26 (24.8) 18 (31.6) 1.21 (0.58–2.56) 0.610
Numbness 13 (12.4) 12 (21.1) 1.74 (0.66–3.68) 0.225
Paraesthesia 13 (12.4) 11 (19.3) 1.40 (0.56–3.51) 0.474
Nausea 16 (15.2) 6 (10.5) 0.58 (0.21–1.67) 0.312
Vomiting 4 (3.8) 1 (1.8) 0.42 (0.04–4.24) 0.460
Abdominal painb 9 (8.7) 7 (12.3) 1.22 (0.40–3.70) 0.731
Skin diseases 8 (7.6) 5 (8.8) 1.12 (0.33–3.78) 0.856
Hair loss 11 (10.5) 6 (10.5) 0.90 (0.31–2.64) 0.851
*Fisher's exact test.
a p-value and OR corresponds to the comparison of ‘preceding dengue infection’ vs. ‘chikungunya-only infection’, adjusted for age and concomitant diabetes
mellitus and cardiovascular disease.
b Total of ‘chikungunya-only infection’ group: n=104.
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dengue disease manifestations were not assessed in this study, they
have been described during co-infection with chikungunya [17]. Under
which circumstances these sequelae present might be understood
through further research regarding (pathophysiology of) chikungunya
and (preceding) dengue (co-)infections. For example, clinical manifes-
tations might be inﬂuenced by order of infection or viral load of the two
viruses.
The high incidence of dengue infection preceding chikungunya
disease and the presence of concurrent infection advocate for a critical
clinical assessment of patients presenting with fever-like diseases in a
chikungunya epidemic against the backdrop of a high dengue en-
demicity. As co-infections are not easily distinguishable from chi-
kungunya-only infections based on acute clinical presentation, con-
comitant dengue might be missed in diagnosis. In the latter case,
dengue disease can still develop into severe disease conditions. Hence,
when a patient presents with acute fever in an area where dengue and
chikungunya circulate, it is important to perform laboratory diagnosis
to conﬁrm presence of these viruses. Additionally, this will provide
valuable information for further chronic disease development, as pa-
tients with preceding dengue infection and chikungunya disease might
have higher chances to develop a severe long-term disease associated
with decreased long-term quality of life [18].
This study described several risk factors for prolonged and severe
long-term chikungunya sequelae. Furthermore, it presents clinical
presentation of preceding dengue infection with chikungunya and
suggest that there might be a link between preceding dengue infection
and aggravated chronic sequelae. However, considering the limitations
of this study, this possible link should be further investigated before a
conclusion can be drawn. The possible consequences, but little knowl-
edge on the consequences of the ongoing spread of these viruses, raise
an urgent call to investigate the clinical presentation and pathophy-
siology of co-circulating (i.e. chikungunya, dengue and Zika) arbo-
viruses.
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Appendix A
The analysis performed in this document includes also the subjects who were not serologically assessed for dengue. This group was included in
the ‘Chikungunya infection’-group, and concerned 137 individuals (of which 65 had data available on acute disease presentation) (See ﬂowchart in
Fig. 1). The remaining individuals were classiﬁed as was described in the main manuscript. At interpretation of these data, this limitation should be
taken into account.
Table A1




and chikungunya (n= 36)
Adjusted ORa (95% CI) Adjusted p-valuea
n (%) n (%)
Acute symptoms (n)b
Fever (n= 117; n=36) 109 (93.2) 32 (88.9) 0.71 (0.19–2.63) 0.603
Headache (n=122; n= 36) 97 (79.5) 30 (83.3) 1.36 (0.50–3.72) 0.364
Orbital pain (n=116; n= 35) 71 (61.2) 21 (60.0) 0.92 (0.42–2.03) 0.841
(continued on next page)
Fig. 2. Chronic chikungunya clinical presentation: Chikungunya-only infection vs. preceding dengue infection.






and chikungunya (n= 36)
Adjusted ORa (95% CI) Adjusted p-valuea
n (%) n (%)
Myalgia (n=121; n= 35) 112 (92.6) 34 (97.1) 4.33 (0.48–39.50) 0.193
Arthralgia (n= 121; n=36) 115 (95.0) 34 (94.4) 1.11 (0.20–6.20) 0.904
Arthritis (n= 114; n=35) 66 (57.9) 26 (74.4) 1.96 (0.83–4.63) 0.126
Rash (n= 121; n=35) 53 (43.8) 15 (42.9) 1.12 (0.51–2.46) 0.782
Nausea/vomiting (n= 121; n=36) 41 (33.9) 12 (33.3) 0.96 (0.43–2.16) 0.927
Diarrhoea (n=120; n= 36) 26 (21.7) 7 (19.4) 0.95 (0.37–2.47) 0.923
Cold shivers (n=119; n=36) 55 (46.2) 17 (47.2) 1.04 (0.48–2.25) 0.917
Cough (n= 121; n=35) 22 (18.2) 2 (5.7) 0.25 (0.05–1.15) 0.075
Haemorrhagic tendencies (n= 121; n=35) 4 (3.3) 0 (0.0) – 0.575*
Icterus (n=120; n= 35) 1 (0.8) 1 (2.9) 1.14 (0.06–21.87) 0.929
*Fisher's exact test.
ap-value and OR corresponds to the comparison of ‘preceding dengue infection and chikungunya’ vs. ‘chikungunya infection’, adjusted for comorbid diabetes
mellitus.
bNumber of subjects in the ‘chikungunya’ infection group and the ‘preceding dengue infection and chikungunya’ group, respectively.
Table A2
Analysis of possible confounders on acute and chronic clinical disease presentation.












n (%) n (%) n (%) n (%)
Age
18–40 28 (22.8) 6 (16.7) 57 (23.6) 9 (15.8)
41–60 71 (57.7) 24 (66.7) 117 (48.3) 37 (64.9)
> 61 24 (19.5) 6 (16.7) 0.614 68 (28.1) 11 (19.3) 0.079
Sex
Male 29 (23.6) 9 (25.0) 67 (27.7) 12 (21.1)
Female 94 (76.4) 27 (75.0) 0.860 175 (72.3) 45 (78.9) 0.307
Co-morbidity
Joint disease 16 (13.0) 6 (16.7) 0.588* 31 (12.8) 10 (17.5) 0.350
Cardiovascular diseasec 26 (21.1) 10 (27.8) 0.402 58 (24.0) 13 (22.8) 0.853
Neurologic disease 1 (0.8) 1 (2.8) 0.403* 8 (3.3) 3 (5.2) 0.444*
Diabetes mellitus 9 (7.3) 8 (22.2) 0.026* 27 (11.2) 11 (19.3) 0.097
*Fisher's exact test.
ap-value corresponds to the comparison between the groups ‘chikungunya infection’ and ‘preceding dengue infection and chikungunya’.
cCardiovascular disease group includes hypercholesterolemia and hypertension.
Table A3
Chronic chikungunya clinical presentation: preceding dengue infection and chikungunya vs. chikungunya infection.
Chikungunya infection (n=242) Preceding dengue infection and chikungunya (n= 57) Adjusted Adjusted
n (%) n (%) ORa (95% CI) p-valuea
Joint pain in the …
upper extremities 106 (43.8) 24 (42.1) 0.78 (0.42–1.43) 0.418
lower extremities 98 (40.5) 31 (54.4) 1.86 (1.02–3.40) 0.044
Back/neck 66 (27.3) 17 (29.8) 1.12 (0.58–2.14) 0.741
Weakness in the …
upper extremities 84 (34.7) 23 (40.4) 1.06 (0.57–1.96) 0.852
lower extremities 77 (31.8) 25 (43.9) 1.71 (0.93–3.12) 0.083
(continued on next page)
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Table A3 (continued)
Chikungunya infection (n=242) Preceding dengue infection and chikungunya (n= 57) Adjusted Adjusted
n (%) n (%) ORa (95% CI) p-valuea
back/neck 53 (21.9) 15 (26.3) 1.18 (0.60–2.32) 0.643
Myalgiab 80 (33.2) 23 (40.4) 1.32 (0.71–2.44) 0.379
Fatigue 73 (30.2) 21 (36.8) 1.30 (0.71–2.41) 0.400
Sleeplessness 63 (26.0) 21 (36.8) 1.64 (0.88–3.05) 0.121
Sombrenessb 40 (16.6) 10 (17.5) 0.99 (0.45–2.17) 0.974
Loss of vitality 57 (23.6) 18 (31.6) 1.36 (0.71–2.59) 0.354
Numbness 38 (15.7) 12 (21.1) 1.30 (0.62–2.72) 0.490
Paraesthesia 24 (9.9) 11 (19.3) 1.85 (0.83–4.11) 0.130
Nausea 27 (11.2) 6 (10.5) 0.86 (0.33–2.23) 0.752
Vomitingb 8 (3.3) 1 (1.8) 0.42 (0.05–3.63) 0.432
Abdominal painb 20 (8.3) 7 (12.3) 1.45 (0.56–3.73) 0.447
Skin diseases 15 (6.2) 5 (8.8) 1.37 (0.47–3.99) 0.567
Hair loss 25 (10.3) 6 (10.5) 1.00 (0.38–2.58) 0.991
*Fisher's exact test.
ap-value and OR corresponds to the comparison of ‘preceding dengue infection and chikungunya’ vs. ‘chikungunya infection’, adjusted for age and concomitant
diabetes mellitus.
bTotal chikungunya infection group n=241.
Fig. A1. Chronic chikungunya clinical presentation: Chikungunya infection vs. preceding dengue infection and chikungunya. **p < 0.050; *p=<0.100.
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